Journal Article Review Epublish 10 citations
PubMed: 40535104 DOI: 10.3892/ol.2025.15130
Treatment of ovarian cancer: From the past to the new era (Review).
Oncol Lett 30(2):384
Authors: Khaled Alrosan, Amjad Z Alrosan, Ghaith B Heilat, Alaa F Alrousan, Omar S Gammoh, Abdelrahim Alqudah, Saba Madae'En, Mohammed J Alrousan
Affiliations
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.
- Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
- Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
- Department of General surgery, King Fahad Specialist Hospital, Tabuk 47717, Saudi Arabia.
Abstract
Ovarian cancer is the most lethal malignancy among female genital cancers, primarily due to the non-specific symptoms, late-stage diagnosis and poor prognosis. Thus, there is a need for accurate and precise diagnostic methods to improve overall survival rates. The aim of the present review was to provide a comprehensive overview of ovarian cancer, including its epidemiology, clinical presentation, etiology, risk factors, staging and diagnostic techniques, in addition to examining the therapeutic approaches, including cytoreductive surgery and adjuvant treatments, while highlighting the mechanisms of resistance to such interventions. Advancements in molecular profiling and a deeper understanding of ovarian tumorigenesis have led to the introduction of novel therapeutic agents currently in clinical use or under clinical investigation. These innovations may improve the management of ovarian cancer, potentially improving survival outcomes.
MeSH
Ovary, Neoplasms, Drug Therapy, Ovarian Neoplasms, Therapeutics, Chemotherapy